Less Ads, More Data, More Tools Register for FREE

Pin to quick picksHutchmed Share News (HCM)

Share Price Information for Hutchmed (HCM)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 293.00
Bid: 290.00
Ask: 293.00
Change: -3.00 (-1.01%)
Spread: 3.00 (1.034%)
Open: 286.00
High: 293.00
Low: 284.00
Prev. Close: 296.00
HCM Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Hutchmed begins registration stage for sovleplenib phase 2/3 trial

Fri, 22nd Mar 2024 10:09

(Alliance News) - Hutchmed (China) Ltd on Friday said it initiated the registration stage of the phase 2/3 clinical trial for sovleplenib, its warm antibody autoimmune hemolytic anemia treatment.

Shares in Hutchmed were down 7.6% to 254.50 pence each in London on Friday morning.

wAIHA is an autoimmune disorder that can lead to anemia and has limited treatment options, Hutchmed said.

The Hong Kong-based developer of treatments for cancer and immunological diseases said this follows positive data from the proof-of-concept phase 2 stage of the trial and subsequent consultation with the China National Medical Products Administration.

If positive, Hutchmed said the data from the trial may be used to support a future new drug application filing.

The first phase 3 patient received their initial dose on Wednesday. Hutchmed said 21 patients have been enrolled in the study so far and approximately 90 more patients are expected to be enrolled to this registration stage.

By Greg Rosenvinge, Alliance News senior reporter

Comments and questions to newsroom@alliancenews.com

Copyright 2024 Alliance News Ltd. All Rights Reserved.

More News
13 May 2016 06:35

Hutchison China MediTech Completes Fruquintinib Trial Enrolment

Read more
20 Apr 2016 15:17

AGM, EGM Calendar - Week Ahead

Read more
13 Apr 2016 16:09

Hutchison China MediTech Raises USD110.2 Million From Listing (ALLISS)

Read more
12 Apr 2016 06:46

Hutchison China MediTech Starts First In Human Trial Of HMPL-689

Read more
29 Mar 2016 10:35

DIRECTOR DEALINGS: Hutchison China Meditech CEO Buys 36,600 ADSs

Read more
21 Mar 2016 13:19

Director dealing: Somero CEO sells half stake for tax bill

(ShareCast News) - Somero Enterprises chief executive Jack Cooney and his wife sold off over £2m of the company's shares, reportedly in order to satisfy a US tax bill. The Cooney's sold 1.4m shares, representing 2.49% of the current issued share capital of the company and approximately half of their

Read more
21 Mar 2016 11:59

DIRECTOR DEALINGS: Hutchison China Non-Executive Ups Interest

Read more
21 Mar 2016 07:52

Hutchison China MediTech Starts Sulfatinib Trial In China

Read more
17 Mar 2016 07:58

Hutchison China MediTech Raises USD101.3 Million From US Listing (ALLISS)

Read more
2 Mar 2016 08:25

Hutchison China MediTech Starts Sulfatinib Phase Two Trials In China

Read more
1 Mar 2016 10:25

WINNERS & LOSERS SUMMARY: Slowing US Growth Knocks Ashtead Shares

Read more
1 Mar 2016 08:31

Hutchison China MediTech Loss Halves As Revenue Doubles

Read more
15 Jan 2016 07:51

Hutchison China MediTech Starts HMPL-523 Trials In Australia

Read more
18 Dec 2015 08:20

Hutchison China MediTech Begins Phase III Trial Of Sulfatinib In China

Read more
9 Dec 2015 08:11

Hutchison China MediTech Nets USD105 Million From Land-Use Rights Deal

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.